Arbutus Biopharma Corp (ABUS) stock news · P/E 5.4, rev $180.1M
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
This ABUS news page leads with what Arbutus Biopharma Corp filed — not a scraped headline mill.
No cached 8-K sentence for ABUS yet. We will not pad this page with generic market recap.
Latest reported ABUS revenue for 2026-06-30 was $180.1M. Net income was $164.6M. Revenue was up 0.6% from 2026-03-31 to 2026-06-30. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the ABUS stock page; for the tape open the quote page.
Not investment advice.